Table 2.
Clinical and parasitological efficacy
| PCR-corrected failure rates | A/L | Quinine | A/P |
| Clinical failure rate day 7 | 0/30 | 0/35 | 0/32 |
| Parasitological failure rate day 7 | 0/30 | 0/35 | 0/32 |
| Intention to treat failure rate* day 7 | 0/30 | 1/35 (~3%) | 0/32 |
| Clinical failure rate day 28 | 0/30 | 3/35 (~9%) | 1/32 (~3%) |
| Parasitological failure rate day 28 | 0/30 | 3/35 (~9%) | 2/32 (~6%) |
| Intention to treat failure rate* day 28 | 0/30 | 7/35 (~20%) | 4/32 (~13%) |
| Recurrent parasitaemia | |||
| Number of patients with recrudescence** (day) | 1 (70) | 4 (24, 28, 28, 40***) | 2 (28, 28) |
| Number of patients with new infection** (day) | 1 (73) | 4 (34, 40, 40***, 65) | 1 (80) |
| Number of patients with P. vivax infection (day) | 2 (28, 28) | 5 (22, 25, 27, 28, 28) | 2 (28, 28) |
| Gametocytaemia | |||
| Number of patients on day 0 | 1 | 3 | 1 |
| Number of patients on day 7 | 2 | 10 | 16 |
| Number of patients on day 28 | 0 | 2 | 0 |
* lost to follow-up included
**P. falciparum: Genotyping by PCR and RFLP patterns of the MSP-1 and MSP-2 gene
*** One sample showed two different clones on day 40, one of them corresponded to the clone on day 0.